Syntis Bio

Syntis Bio is a private, clinical-stage biotech founded in 2021 and based in Cambridge, Massachusetts. The company is pioneering a novel oral drug delivery platform, SYNT™, which uses a bio-inspired polymer to line the small intestine, thereby modulating nutrient absorption and enabling the oral delivery of peptides, enzymes, and other biologics. With a $38 million financing round closed in 2025, Syntis is advancing a pipeline led by SYNT-101 for obesity, which has entered Phase 1/1b trials. The company leverages world-class scientific founding from MIT and a leadership team with deep experience in bringing novel therapeutics and diagnostics to market.

SYNT™ (SYNthetic Tissue-lining) platform: a bio-inspired polymer coating applied to the small intestine to create a transient barrier for nutrient modulation or to enhance local drug efficacy for oral delivery of biologics.

In obesity, Syntis competes with dominant pharmaceutical companies marketing GLP-1 agonists (e.g., Novo Nordisk, Eli Lilly) and other modalities, offering a distinct, locally-acting mechanical/metabolic mechanism. In drug delivery, it competes with other platforms aiming for oral biologic delivery, but its transient tissue-coating approach appears to be a unique strategy.